Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib

Pediatric Blood & Cancer(2020)10.1002/pbc.28814Source: DataRank Database

Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib is a research paper published in Pediatric Blood & Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

4 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: closedTopics (40)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Marta Salek ORCID,Noah D. Sabin ORCID,Meredith Canale,Santhosh A. Upadhyaya ORCID,Melissa S. Bourque ORCID

Live enrichment

PubMed:33211390 OpenAlex:https://openalex.org/W3098437305

National Science Foundation

Grant: CA21765

American Lebanese Syrian Associated Charities

closedLicense: http://onlinelibrary.wiley.com/termsAndConditions#am

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28814

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/pbc.28814

publisherhttps://onlinelibrary.wiley.com/doi/am-pdf/10.1002/pbc.28814

journalhttps://doi.org/10.1002/pbc.28814

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33211390

Fields of Study

Melanoma and MAPK PathwaysColorectal Cancer Treatments and StudiesCancer Mechanisms and TherapyAdolescentBrain NeoplasmsGangliogliomaHumansImidazolesMitogen-Activated Protein Kinase KinasesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesVemurafenib

MeSH Terms

VemurafenibAdolescentBrain NeoplasmsHumansImidazolesOximesPyridonesPyrimidinonesGangliogliomaMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins B-raf

Keywords

VemurafenibTrametinibDabrafenibMedicineGangliogliomaCancer researchMEK inhibitorOncologyInternal medicineMetastatic melanomaMelanomaKinaseGeneticsMAPK/ERK pathwayBiology

Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib

FAIR Checklist

Authors (5)

Funding (2 grants)

Open Access

Topics